Fate Therapeutics (FATE) Prices 4.421M Share Common Offering at $85/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Oil settles up over $2 as Iran war stalemate stokes supply concerns
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Trump threatens to bomb Oman over Iran stance
Pre-Open Stock Movers 01/05: (BPFH) (MRKR) (FUBO) Higher; (EGHT) (FATE) (VRAY) Lower (more...)
January 5, 2021 9:30 AM ESTPre-Open Stock Movers:
Boston Private Financial Holdings, Inc. (NASDAQ: BPFH) 28.3% HIGHER; SVB Financial Group (NASDAQ: SIVB), the parent of Silicon Valley Bank, the bank of the world's most innovative... More
After-Hours Stock Movers 01/04: (IO) (LIFE) (AIH) Higher; (FATE) (GBIO) Lower (more...)
January 4, 2021 6:02 PM ESTAfter-Hours Stock Movers:
ION Geophysical Corporation (NYSE: IO) 17.8% HIGHER; announced the first proprietary commercial deployment of the Companys Gemini extended frequency source technology for a Super Major. Following the technologys commercialization in September, energy companies have specified Gemini in a number of proprietary tenders, the first of which... More
Fate Therapeutics (FATE) Announces Proposed $350M Share Common Offering
January 4, 2021 4:02 PM ESTFate Therapeutics Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that it has commenced an underwritten public offering of $350 million of shares of common stock. Fate Therapeutics intends to use the net proceeds from the offering to fund clinical... More
